Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
09 December 2022 - 12:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians, and partners concerned with retinal health
and maintaining better vision longer, today announced that it has
agreed to an amendment to its existing loan and security agreement
with its debt facility partner, SLR Investment Corp (“SLR”) to
extend the interest-only period through March 31, 2023 with the
possibility of extending to July 1, 2023.
“We have had a long and productive relationship with SLR and
appreciate the opportunity to amend this agreement to extend the
interest-only period,” said Rick Eiswirth, President and CEO of
Alimera. “As we enter 2023, we will work closely with SLR to
evaluate and employ the best long-term options for both companies.
We look forward to reporting on further developments, in due
course.”
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose
mission is to be invaluable to patients, physicians and partners
concerned with retinal health and maintaining better vision longer.
For more information, please visit www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Any such forward-looking statements will be based on current
expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change these
expectations, and could cause actual results to differ materially
from those projected in these forward-looking statements.
Meaningful factors that could cause actual results to differ
include, but are not limited to Alimera’s inability to work closely
with SLR to evaluate and employ the best long-term options for both
companies, as well as the other factors discussed in the “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” sections of Alimera’s Annual
Report on Form 10-K for the year ended December 31, 2021 and
Alimera’s Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2022, June 30, 2022, and September 30, 2022 which are on
file with the SEC and are available on Alimera’s website and the
SEC’s website at http://www.sec.gov.
Alimera undertakes no obligation to publicly update or revise
any of the forward-looking statements made in this press release,
whether as a result of new information, future events or otherwise,
except as required by law. Therefore, you should not rely on these
forward-looking statements as representing Alimera’s views as of
any date after today.
For
investor inquiries: |
For
media inquiries: |
Scott Gordon |
Jules Abraham |
for Alimera Sciences |
for Alimera Sciences |
scottg@coreir.com |
julesa@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2023 to Mar 2024